Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 4, 2009 Brian Orelli	The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.
The Motley Fool September 14, 2009 Brian Orelli	The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri.
The Motley Fool February 11, 2010 Brian Orelli	Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
The Motley Fool September 30, 2009 Brian Orelli	More Questions Than Answers From Elan Things that make you go hmmm.
The Motley Fool February 9, 2011 Brian Orelli	Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool December 19, 2011 Brian Orelli	Elan Turns It Around in 2011 Let's hope next year is as productive.
The Motley Fool August 27, 2009 Brian Orelli	Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan
The Motley Fool August 26, 2008 Brian Lawler	FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool June 1, 2009 Brian Orelli	Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool April 17, 2009 Brian Orelli	When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future?
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool February 10, 2009 Brian Orelli	Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma.
The Motley Fool August 10, 2010 Brian Orelli	Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option.
The Motley Fool October 24, 2007 Brian Lawler	Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results.
The Motley Fool December 28, 2010 Brian Orelli	No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005.
The Motley Fool February 28, 2008 Brian Lawler	A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool October 28, 2011 Brian Orelli	Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever.
The Motley Fool January 25, 2010 Brian Orelli	Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
Chemistry World February 8, 2013 Andrew Turley	Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool October 25, 2007 Brian Lawler	Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation?
The Motley Fool January 5, 2010 Brian Orelli	Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool October 30, 2007 Brian Lawler	Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note.
The Motley Fool October 26, 2009 Brian Orelli	For Tysabri, 23 Is 10 Too Many The side effect rate is important.
The Motley Fool April 23, 2009 Brian Orelli	Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them.
The Motley Fool November 21, 2007 Brian Lawler	Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note.
The Motley Fool October 5, 2006 Brian Lawler	Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up.
The Motley Fool May 9, 2011 Brian Orelli	In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million.
The Motley Fool April 25, 2007 Brian Lawler	Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note.
The Motley Fool August 4, 2010 Mac Greer	One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan.
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
The Motley Fool March 26, 2009 Brian Orelli	R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales.
The Motley Fool June 30, 2009 Brian Orelli	Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
The Motley Fool February 27, 2009 Brian Orelli	Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already.
The Motley Fool January 12, 2010 Brian Orelli	Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status?
The Motley Fool October 22, 2008 Brian Orelli	Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places.